Clinical trial NCT02187471: Treatment of Pain Associated With Fibromyalgia
Official title: A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pain Associated With Fibromyalgia
Keywords: pain
fibromyalgia
Lead sponsor: Daiichi Sankyo
Sponsor class: INDUSTRY
Collaborators: name: Syneos Health
First posted: 2014-07-11
Enrollment: 1301
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo.

Weekly ADPS is based on daily pain scores reported by the subject that best describes his or her worst pain over the previous 24 hours.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Able to give written informed consent
* Able to complete subject-reported questionnaires per the investigator's judgment
* At screening, subjects must meet the 1990 American College of Rheumatology (ACR) criteria for FM, i.e. widespread pain present for at least 3 months and pain in at least 11 of 18 specific tender point sites. In addition, the 2010 ACR criteria must be met:
* Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5, or WPI 3 to 6 and SS scale score ≥ 9
* Symptoms have been present at a similar level for at least 3 months
* The subject does not have a disorder that would otherwise explain the pain
* ADPS of ≥ 4 on the 11-point numeric rating scale (NRS) over the past 7 days prior to randomization (based on completion of at least 4 daily pain diaries during the 7-day baseline period prior to randomization)
* Subject must have documented evidence of a fundoscopic examination (with pupil dilation) within 12 months prior to screening or at screening.
* Women of child-bearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy during the study and for 4 weeks after study completion.

Exclusion Criteria:

* Clinically significant unstable neurologic, psychiatric, ophthalmologic, hepatobiliary, respiratory, or hematologic illness or unstable cardiovascular disease (e.g. severe hypotension, uncontrolled cardiac arrhythmia, or myocardial infarction) or any other concurrent disease within 12 months prior to screening that in the opinion of the investigator would interfere with study participation or assessment of safety and tolerability
* Anticipation of initiation or significant change to normal daily exercise routines or need for ongoing use of concomitant medications or non-pharmacological pain management techniques that may confound assessments of efficacy and/or safety
* Unable to undergo pre-study washout of prohibited concomitant medications
* Subjects who are at risk of suicide as defined by their responses to the Columbia-Suicide Severity Rating Scale (C-SSRS) or in the opinion of the investigator. Note: Patients answering "yes" to any of the C-SSRS questions at screening must be excluded. Such patients should be referred immediately to a mental health professional for appropriate evaluation.
* Current severe or uncontrolled major depressive disorder or anxiety disorders as assessed by the Mini-international Neuropsychiatric Interview (MINI) mild to moderate major depression or anxiety disorders are permitted provided that the investigator assesses the patient as clinically stable and appropriate for entry into the study.
* Any diagnosis of lifetime bipolar disorder or psychotic disorder
* Subjects with pain due to other conditions (e.g. diabetic peripheral neuropathic pain or post-herpetic neuralgia) that in the opinion of the investigator, would confound assessment or self-evaluation of the pain associated with FM.
* Subjects with pain due to any widespread inflammatory musculoskeletal disorder (e.g. rheumatoid arthritis, lupus) or widespread rheumatic disease other than FM.
* Abuse or dependence of prescription medications, street drugs, or alcohol within the last 1 year
* Any history of a malignancy other than basal cell carcinoma within the past 5 years
* A diagnosis of untreated sleep apnea or initiation of treatment for sleep apnea within the past 3 months
* Pregnancy or breast-feeding, or intent to become pregnant during the study period
* Subject is currently enrolled in or has not yet completed at least 30 days since ending another investigational device or drug study or is receiving other investigational agents.
* Known hypersensitivity to alpha2-delta (α2δ) ligands or other components of the study medications. Note: Prior exposure to DS-5565 is allowed, as long as hypersensitivity to DS-5565 was not observed.
* Subjects who are unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the investigator to be unlikely to complete the study.
* Abnormal investigative tests (i.e. electrocardiograms \[ECGs\]) and laboratory values judged by the investigator to be clinically significant at screening, with particular focus on: a. Abnormal renal function defined as calculated creatinine clearance (CrCl) \< 60 mL/min determined by the central laboratory using the modified Cockcroft-Gault equation; blood urea nitrogen\> 1.5 × upper limit of normal (ULN); creatine kinase \> 3.0 × ULN; serum creatinine \> 1.6 mg/dL (\> 141.4 μmol/L); b. Abnormal liver function defined as aspartate aminotransferase (AST) \> 2.0 × ULN, alanine aminotransferase (ALT) \> 2.0 × ULN; alkaline phosphatase \> 1.5 × ULN; total bilirubin\> 1.2 × ULN. If a subject has total bilirubin \> 1.2 ULN, unconjugated and conjugated bilirubin fractions should be analyzed and only subjects documented to have Gilbert's syndrome may be enrolled.

Primary outcomes:
measure: Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) Among Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
Secondary outcomes:
measure: Number of Participants Who Answered "Much Improved or Better" in Patient Global Impression of Change at Week 13 Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Change From Baseline to Week 13 in Average Score on the Fibromyalgia Index Questionnaire (FIQ) in Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Number of Participants Classified As Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Week 13 postdose
measure: Change From Baseline to Week 13 in Multidimensional Fatigue Inventory (MFI-20) General Fatigue Score Among Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Change From Baseline to Week 13 in Hospital Anxiety and Depression Scale (HADS) Measure Among Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Change From Baseline to Week 13 in Short Form 36 (SF-36) Measure Among Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Change From Baseline to Week 13 in EuroQol Five Dimensions Questionnaire (EQ-5D) Measure Among Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Change From Baseline to Week 13 in Average Daily Sleep Interference Score (ADSIS) Among Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Number of Participants Reporting Optimal Sleep at Week 13 on the Medical Outcomes Study (MOS) Sleep Scale Among Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Week 13 postdose
measure: Change From Baseline at Week 13 in the Brief Pain Inventory Short Form (BPI-SF) Measure Among Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Baseline up to Week 13 postdose
measure: Proportion of Days a Rescue Medication Was Used Among Participants Receiving DS-5565, Pregabalin, or Placebo
timeFrame: Week 1 to Week 13 postdose
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: Huntsville
country: United States
state: Alabama
city: Phoenix
country: United States
state: Arizona
city: Scottsdale
country: United States
state: Arizona
city: Tempe
country: United States
state: Arizona
city: Tucson
country: United States
state: Arizona
city: Anaheim
country: United States
state: California
city: Covina
country: United States
state: California
city: El Cajon
country: United States
state: California
city: Encino
country: United States
state: California
city: Huntington Beach
country: United States
state: California
city: Lakewood
country: United States
state: California
city: Lomita
country: United States
state: California
city: Los Angeles
country: United States
state: California
city: National City
country: United States
state: California
city: Northridge
country: United States
state: California
city: Oceanside
country: United States
state: California
city: Sacramento
country: United States
state: California
city: Upland
country: United States
state: California
city: Walnut Creek
country: United States
state: California
city: Boca Raton
country: United States
state: Florida
city: DeLand
country: United States
state: Florida
city: Edgewater
country: United States
state: Florida
city: Fort Lauderdale
country: United States
state: Florida
city: Fort Myers
country: United States
state: Florida
city: Hialeah
country: United States
state: Florida
city: Largo
country: United States
state: Florida
city: Lauderdale Lakes
country: United States
state: Florida
city: Maitland
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Orlando
country: United States
state: Florida
city: Sunrise
country: United States
state: Florida
city: Tamarac
country: United States
state: Florida
city: Tampa
country: United States
state: Florida
city: Vero Beach
country: United States
state: Florida
city: West Palm Beach
country: United States
state: Florida
city: Winter Haven
country: United States
state: Florida
city: Winter Park
country: United States
state: Florida
city: Dawsonville
country: United States
state: Georgia
city: Marietta
country: United States
state: Georgia
city: Smyrna
country: United States
state: Georgia
city: Chicago
country: United States
state: Illinois
city: Evansville
country: United States
state: Indiana
city: Granger
country: United States
state: Indiana
city: Overland Park
country: United States
state: Kansas
city: Owensboro
country: United States
state: Kentucky
city: Lake Charles
country: United States
state: Louisiana
city: New Orleans
country: United States
state: Louisiana
city: Frederick
country: United States
state: Maryland
city: Brockton
country: United States
state: Massachusetts
city: North Dartmouth
country: United States
state: Massachusetts
city: Ann Arbor
country: United States
state: Michigan
city: Ann Arbor
country: United States
state: Michigan
city: Lansing
country: United States
state: Michigan
city: Rochester Hills
country: United States
state: Michigan
city: Florissant
country: United States
state: Missouri
city: Hazelwood
country: United States
state: Missouri
city: O'Fallon
country: United States
state: Missouri
city: Bellevue
country: United States
state: Nebraska
city: Newington
country: United States
state: New Hampshire
city: Albuquerque
country: United States
state: New Mexico
city: Brooklyn
country: United States
state: New York
city: Cedarhurst
country: United States
state: New York
city: Rochester
country: United States
state: New York
city: Charlotte
country: United States
state: North Carolina
city: Raleigh
country: United States
state: North Carolina
city: Winston-Salem
country: United States
state: North Carolina
city: Minot
country: United States
state: North Dakota
city: Cincinnati
country: United States
state: Ohio
city: Columbus
country: United States
state: Ohio
city: Dayton
country: United States
state: Ohio
city: Middleburg Heights
country: United States
state: Ohio
city: Oklahoma City
country: United States
state: Oklahoma
city: Portland
country: United States
state: Oregon
city: Altoona
country: United States
state: Pennsylvania
city: Media
country: United States
state: Pennsylvania
city: Wyomissing
country: United States
state: Pennsylvania
city: Greenville
country: United States
state: South Carolina
city: Mount Pleasant
country: United States
state: South Carolina
city: Chattanooga
country: United States
state: Tennessee
city: Franklin
country: United States
state: Tennessee
city: Knoxville
country: United States
state: Tennessee
city: Memphis
country: United States
state: Tennessee
city: Austin
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Lake Jackson
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Norfolk
country: United States
state: Virginia
city: Richmond
country: United States
state: Virginia
city: Bellevue
country: United States
state: Washington
city: Richland
country: United States
state: Washington
city: Caba
country: Argentina
state: Buenos Aires
city: La Plata
country: Argentina
state: Buenos Aires
city: Lanús
country: Argentina
state: Buenos Aires
city: Mar Del Plata
country: Argentina
state: Buenos Aires
city: Quilmes
country: Argentina
state: Buenos Aires
city: San Fernando
country: Argentina
state: Buenos Aires
city: Rosario
country: Argentina
state: Santa FE
city: Cordoba
country: Argentina
city: San Miguel de Tucuman
country: Argentina
city: Santa Fe
country: Argentina
city: Klagenfurt
country: Austria
city: Senftenberg
country: Austria
city: Vienna
country: Austria
city: Minsk
country: Belarus
city: Vitebsk
country: Belarus
city: Brussels
country: Belgium
city: Edegem
country: Belgium
city: Gozee
country: Belgium
city: Oostham
country: Belgium
city: Antofagasta
country: Chile
city: Providencia
country: Chile
city: Puerto Varas
country: Chile
city: Vina Del Mar
country: Chile
city: Barranquilla
country: Colombia
city: Bogota
country: Colombia
city: Haifa
country: Israel
city: Kfar Saba
country: Israel
city: Ramat Gan
country: Israel
city: Tel-aviv
country: Israel
city: Cuautitlán Izcalli
country: Mexico
city: Durango
country: Mexico
city: Guadalajara
country: Mexico
city: Leon
country: Mexico
city: Mexico City
country: Mexico
city: Elblag
country: Poland
city: Gdansk
country: Poland
city: Katowice
country: Poland
city: Kraków
country: Poland
city: Lublin
country: Poland
city: Nadarzyn
country: Poland
city: Nowa Sol
country: Poland
city: Torun
country: Poland
city: Tychy
country: Poland
city: Warsaw
country: Poland
city: Aveiro
country: Portugal
city: Braga
country: Portugal
city: Guimaraes
country: Portugal
city: Lisboa
country: Portugal
city: Ponte de Lima
country: Portugal
city: Porto
country: Portugal
city: Vila Nova de Gaia
country: Portugal
city: Ljubljana
country: Slovenia
city: Slovenj Gradec
country: Slovenia
city: Alicante
country: Spain
city: Barcelona
country: Spain
city: Elche
country: Spain
city: Granada
country: Spain
city: Guadalajara
country: Spain
city: Madrid
country: Spain
city: Santiago de Compostela
country: Spain
city: Sevilla
country: Spain
city: Geneva
country: Switzerland
city: St. Gallen
country: Switzerland
Study officials:
affiliation: Daiichi Sankyo
name: Global Clinical Leader
role: STUDY_DIRECTOR
References:
citation: Arnold LM, Whitaker S, Hsu C, Jacobs D, Merante D. Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study. Curr Med Res Opin. 2019 Oct;35(10):1825-1835. doi: 10.1080/03007995.2019.1629757. Epub 2019 Jul 9.